FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

SOLV

SolventumNYSE · Health Care Technology · Health Care
Previous close
81.33
Change
−2.23 / −2.67%
FinDog View
Neutral
52-Week Range ?
62.38 – 94.16
P/E (TTM) ?
9.9
Forward P/E ?
11.4
Based on consensus earnings for the next 12 months
Market Cap
$13.8B
1M
−7.74%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.1M / 1.1M
0.98× average
Latest earnings analysisFY2026 Q2Reported 2026-08-05

Solventum Q2 FY2026: organic sales +9.5%, adjusted EPS $2.55, guidance up

Solventum beat on adjusted profit and raised full-year guidance on organic sales, adjusted EPS and free cash flow, so the quarter reads Bullish — but much of the strength came from items that will not repeat. Read the top line two ways: reported sales rose 2.2% while organic sales rose 9.5%, because the Purification and Filtration business sold in September 2025 still sat in last year's reported numbers.

Read the full analysis →
Revenue$2.21BYoY +2.20%
EPS (non-GAAP)$2.55Beatest. $1.94
Next-day move−5.16%

Price History

Closing price · USD1M6M1Y5Y
60708090100EFY26 Q2 EarningsEFY26 Q1 Earnings2026-042026-062026-082026-092026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 10.81M6M1Y5Y
0102030402024-042024-112025-072026-032026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-05
in 4 days · time TBD
Consensus EPS
$1.38
Last quarter EPS $2.55
Avg. next-day move over the last 6 reports
±4.5%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 42 of its 5-year rangeMid-range
5-year range 7.3 – 34.1 · Median 10.8
Last 4 quarters: $355M in buybacks + $0 in dividends, 2.57% of market cap combined
P/E (TTM)
9.9
P/B
3.0
P/S
1.7
PEG
0.04
Earnings Reaction
Over the last 6 reports, the stock moved ±4.5% on average on the first trading day after, rising 4 times
Most recent −5.16%
Volatility & Correlation
1-year beta 0.57 · Correlation with S&P 500 0.24Low beta
Annualized volatility 30% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q22.21+2.2%—0.180.090.140.53
FY2026 Q12.01−3.0%—0.080.01-0.270.07
FY2025 Q42.00−3.7%—0.130.060.030.37
FY2025 Q32.10+0.7%—1.691.27-0.027.22
FY2025 Q22.16+3.8%—0.210.090.060.51
FY2025 Q12.07+2.7%—0.150.14-0.080.78
FY2024 Q42.08+1.9%—0.140.030.090.18
FY2024 Q32.08+0.4%—0.280.120.080.70
FY2024 Q22.08+0.2%—0.240.090.300.51
FY2024 Q12.02+0.2%—0.380.240.341.37
FY2023 Q42.04——0.410.270.461.57
FY2023 Q32.07——0.500.460.432.66

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView